Overview of Femar

What is Femar? (Letrozole: Definition, Class, and Action)

Property	Description
Active Ingredient	Letrozole
Form	Film-coated Oral Tablet
Pharmacological Class	Third-Generation Aromatase Inhibitor
General Purpose	To lower the body's circulating estrogen levels
Origin	Synthetic and Nonsteroidal

What Type of Medicine is Femar? Classification and Origin

Femar is a prescription-only pharmaceutical preparation containing the active ingredient Letrozole, which is recognized globally as a potent Third-Generation Aromatase Inhibitor. This classification places it within the domain of endocrine therapy, a targeted approach supported by clinical investigation in managing hormone-sensitive conditions. Letrozole is a synthetic compound, chemically designed as a nonsteroidal triazole derivative. This engineered structure is a key differentiating factor, enabling a highly focused therapeutic effect compared to some older hormonal agents. Pharmacological studies confirm the drug’s high specificity and effectiveness in its designated action.

Composition and Pharmaceutical Form

The medicine is supplied as a film-coated oral tablet, intended to be swallowed, and is a single-ingredient product where the therapeutic action is derived exclusively from the active substance, Letrozole. Unlike some medications that rely on a combination of active components, Femar provides a focused treatment by delivering a pure dose of the inhibitor. The active compound is integrated into a solid excipient base (inactive ingredients) necessary to ensure a stable, measured dose and facilitate safe oral administration. This oral form distinguishes it from agents requiring intravenous delivery, offering a standard, convenient route of administration.

The General Purpose of Aromatase Inhibition

The primary purpose of Femar is to significantly reduce the production of the hormone estrogen throughout the body. It achieves this by functioning as a highly potent and selective competitive inhibitor of the aromatase enzyme system. This enzyme is the biological mechanism responsible for converting other hormones (androgens) into circulating estrogen in peripheral tissues. The resulting reduction in estrogen levels is the foundational therapeutic objective, providing a critical tool in scenarios where the removal of this hormonal stimulus is necessary to manage a biological process.

What side effects are possible with Femar?

Possible Side Effects and Safety Information

The safety profile for Femar (Letrozole) is formally documented by government regulatory bodies and primarily reflects the consequences of reducing the body's circulating estrogen levels. Adverse reactions are classified by frequency and system involvement, consistent with regulatory reporting standards (e.g., EMA SmPC, FDA Prescribing Information).

Adverse Reaction Scope

Classification	Examples of Officially Listed Reactions
Very Common (ge 1/10)	Hot flashes (flushing), arthralgia (joint pain), fatigue (asthenia), hyperhidrosis (increased sweating), and hypercholesterolemia (high cholesterol).
Common (ge 1/100 to <1/10)	Headache, dizziness, nausea, vomiting, bone pain, osteoporosis, peripheral oedema, and bone fractures.
Uncommon / Rare	Ischemic cardiac events, cerebrovascular accident, thromboembolic events, tendonitis, and tendon rupture (rare).

Serious Adverse Reactions and Safety Constraints

Official labeling documents the potential for certain serious events, including cardiovascular and cerebrovascular events, and consequences related to bone health such as osteoporosis and fractures, particularly with long-term use. Monitoring of Bone Mineral Density (BMD) and serum cholesterol should be considered.

The medicine is contraindicated in premenopausal women, during pregnancy, and during lactation. Due to reports of fatigue, dizziness, and somnolence, the label notes the medicine has a minor influence on the ability to drive and use machinery. Patients with severe hepatic impairment are noted for experiencing increased systemic exposure and require close supervision.

Overdose and Emergency Response

Regulatory documentation on Femar (Letrozole) overdose primarily focuses on required emergency actions and the specific management approach. Isolated cases of overdose have been reported in the post-marketing setting, but these were generally documented as not associated with serious adverse reactions. As a result of the limited clinical data, a characteristic human symptom profile for over-use is not formally described in the official prescribing information.

The official regulatory guidance for managing an overdose states that treatment must be symptomatic and supportive, as no specific treatment or antidote is known. The management focus is placed on stabilizing the patient using general supportive measures. The regulatory sections do not define specific monitoring requirements or population-specific risks for overdose, such as those related to renal or hepatic impairment.

Urgent Medical Attention Requirements

Immediate medical advice must be sought from a doctor or hospital upon suspicion of over-use. Specific regulatory instructions mandate contacting emergency services (911) immediately if certain severe life-threatening signs are observed. These critical signs include collapse, experiencing a seizure, profound trouble breathing, or an inability to be awakened.

Therapeutic Uses of Femar

What Femar Treats: Main Uses and Benefits

The therapeutic application of Femar (Letrozole) is relevant for managing hormone receptor-positive malignancies in situations where the disease is driven by hormonal factors. This use is commonly employed to support long-term management of breast cancer.

This medication is broadly indicated for postmenopausal women with hormone receptor-positive breast cancer, addressing clinical scenarios that include early-stage adjuvant therapy, extended adjuvant use after initial treatment, and the systemic management of advanced or metastatic disease.

“This type of therapy is relevant for supporting control over disease progression for estrogen-sensitive tumors.”

This medication is utilized in several contexts, including:

Disease Control After Primary Treatment (Adjuvant & Extended Use): This domain covers the long-term use of the medication following initial local therapy, aimed at supporting management of the risk of disease recurrence and the development of new tumors.
Systemic Management of Advanced and Metastatic Disease: This cluster focuses on the application to treat established cancer that is widespread, where hormonal influence is key. This systemic use is relevant for managing the progression of tumor growth and spread, offering support for control over the condition’s course.
Reduction of Tumor Size Before Surgery (Neo-Adjuvant): Femar may assist with managing the size of the cancerous mass before surgery, which may support patients during this clinical scenario.

Quick Fact: Management of Disease Progression Risk Femar is primarily used in postmenopausal women to help manage the risk associated with disease progression and recurrence and supports long-term disease management.

Regulatory References

U.S. National Library of Medicine (NIH) DailyMed label

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Femar — Official Regulatory Information

The eligibility for Femar (Letrozole) is strictly defined by regulatory authorities, with use primarily allowed in postmenopausal women.

Category	Regulatory Status
Populations Allowed	Postmenopausal women; Adults (typically ge 18 years); Older adults (no dose adjustment required based on age alone).
Contraindicated	Women who are pregnant; Women who are breastfeeding; Patients with known hypersensitivity to letrozole or its excipients; Females of premenopausal status [1.3, 2.3, 4.2].

Eligibility and Condition-Specific Restrictions

Condition/Age Group	Official Regulatory Rule
Severe Hepatic Impairment	Requires close supervision; A 50% dose reduction is recommended for patients with cirrhosis and severe hepatic dysfunction [3.3, 2.3].
Severe Renal Impairment	Insufficient data are available for creatinine clearance mathbf< 10 mL/min; Use must be carefully considered [4.4].
Pediatric Use	Safety and efficacy have not been established; Use is not recommended in children and adolescents [4.4].

The official labeling establishes that Femar is contraindicated in women who are pregnant, due to the potential for fetal harm, and in any patient with a known allergy to the medication. This restriction requires women of childbearing potential to confirm postmenopausal status or use effective contraception. [1.6, 2.4]

What should I know about interactions with other medicines?

The official regulatory documentation for Femar (Letrozole) establishes specific interaction patterns based on pharmacodynamic and pharmacokinetic principles. Co-administration with estrogen-containing therapies, such as hormone replacement therapy, is formally contraindicated by regulatory agencies. This is due to a direct pharmacodynamic antagonism where exogenous estrogens counteract the core pharmacological action of Letrozole.

The co-administration of Tamoxifen and other anti-oestrogens should be avoided as these substances may diminish the intended effect of Letrozole. Tamoxifen specifically causes a pharmacokinetic interference that substantially reduces Letrozole plasma concentrations by an average of 38%.

Letrozole is metabolized by CYP2A6 and CYP3A4. Due to in vitro data showing inhibition of CYP2A6 and CYP2C19, caution is formally indicated when co-administering medicinal products with a narrow therapeutic index that rely on these enzymes for elimination, such as Phenytoin or Clopidogrel. No clinically significant interactions were found when co-administered with Cimetidine or Warfarin.

Furthermore, the official label states that food does not affect drug absorption. A population-specific note highlights that patients with severe hepatic impairment (Child-Pugh C) are documented to have approximately twice the systemic drug exposure due to reduced systemic clearance.

Mechanism of Action

Targeted Aromatase Enzyme Inhibition

Femar (Letrozole) acts within the domain of enzyme-mediated signaling by functioning as a highly specific competitive inhibitor of the Aromatase enzyme ( CYP19A1). This molecular action directly suppresses the key biological process: the conversion of androgens to estrogens—the reaction that sustains hormonal levels.

Profound Systemic Estrogen Deprivation

By blocking the enzyme, the drug modifies the early molecular steps that shape the systemic physiological outcome, leading to a profound, measurable reduction in circulating estrogen concentrations (typically >90%). This mechanistic cascade results in an altered state within estrogen-sensitive biological pathways by reducing the concentration of hormonal stimulus across the body's tissues.

Endocrine Feedback Axis Modulation

The resulting drop in estrogen engages mechanisms that influence the feedback regulation within the Hypothalamic-Pituitary-Gonadal ( HPG) axis. This alteration triggers a compensatory rise in pituitary gonadotropins ( LH and FSH), a predictable physiological adjustment that leads to a functional limitation of the mechanism in contexts like premenopausal ovarian function.

Dosage and Administration Information

How to use Femar

The administration of Femar (Letrozole) follows a standardized, fixed-dose protocol. The medication is supplied as a 2.5 mg film-coated oral tablet and must be swallowed whole with water. It is taken once daily and can be administered with or without food, without regard to mealtimes.

The standard dose is a single 2.5 mg tablet for all approved indications; no dose titration is required. The duration of therapy depends on the clinical context. For long-term use, such as adjuvant and extended adjuvant treatment, administration typically continues for five years or until evidence of disease recurrence. For managing advanced or metastatic disease, treatment is continued until tumor progression is observed. Pre-operative (neo-adjuvant) administration may be used for a period of four to eight months.

Population-Specific Administration

Specific modifications are required for patients with severe liver impairment. While no dose adjustment is required for geriatric patients or those with mild-to-moderate hepatic impairment, the regimen is modified for those with severe hepatic impairment (Child-Pugh C). For this group, the dose is 2.5 mg administered every other day.

Handling a Missed Dose

If a dose is missed, it should be taken as soon as remembered, unless the next scheduled dose is due within two to three hours. In that case, the missed dose must be skipped, and the patient must not take two doses to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Femar (Letrozole)

This section summarizes the official clinical research and scientific evidence that contributes to the understanding of Femar (Letrozole), focusing only on the design and scope of key trials, systematic reviews, and meta-analyses, and remaining strictly non-advisory.

Evidence for Initial Adjuvant Therapy in Early Breast Cancer

Studies monitored the use of Femar as initial adjuvant therapy in postmenopausal women with hormone receptor-positive early breast cancer following surgery. Research examined large, multinational Randomized Controlled Trials (RCTs). These trial designs evaluated Femar against other established hormonal agents, and research monitored long-term outcomes. The primary endpoints that research examined were the long-term patterns of disease recurrence, known as Disease-Free Survival (DFS), and Overall Survival (OS).

Findings describe patterns observed in the studies over several years of observation. Studies report how symptoms evolved in the observed populations when comparing the different treatments. Evidence contributes to understanding symptom patterns over the required five-year treatment duration.

Evidence for Extended Adjuvant Use

Extended adjuvant use of Femar beyond the initial five years of hormonal therapy was evaluated in postmenopausal women who remained disease-free. This research primarily involved large, double-blind, Placebo-Controlled RCTs. The main outcomes that research examined were measures of ongoing disease-free status and the incidence of cancer developing in the opposite breast.

Research highlights changes measured during the study period when comparing the groups. A key limitation is that some major studies were stopped early, complicating the interpretation of final results, and evidence quality varies across studies depending on the length of post-crossover follow-up.

Evidence for Systemic Management of Advanced and Metastatic Disease

Femar was evaluated in studies as an initial systemic therapy for advanced or metastatic breast cancer that is hormone receptor-positive. These Phase III Randomized Controlled Trials research examined the progression of the widespread disease. Key outcomes that research examined included Time to Progression (TTP), which is an outcome related to the length of time before recorded disease worsening, and the Objective Response Rate (ORR), which is an outcome related to the degree of measurable tumor shrinkage.

Research Gaps and Uncertainty

Despite extensive research, data for certain groups remain insufficient, such as for premenopausal women or patients with significant pre-existing comorbidities. Subgroup findings are uncertain when trying to generalize research to populations that were not well represented in the major trials. Furthermore, comparative evidence is lacking for Femar against the very newest hormonal and targeted therapies that have been approved more recently, as research is ongoing in those areas.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Femar (FAQ)

Q: How quickly does Femar typically start to work?

Studies and official information indicate that Femar reaches steady-state plasma concentrations generally within two to six weeks of continuous daily use. Steady-state refers to the point where the concentration of the medicine in the body remains consistent. This level is associated with the full establishment of the medication’s action, which is a profound reduction in estrogen.

Q: Can I still drive while taking Femar?

The official product information advises caution regarding driving or operating machinery. This warning is based on reports that side effects like fatigue, dizziness, and somnolence (sleepiness) may occur. Patients are generally advised to be cautious when performing tasks that require full mental alertness.

Q: Is it normal to feel tired when starting Femar?

Fatigue, also known as asthenia, is listed in the official safety information as a very common side effect, meaning it is reported in at least 1 out of every 10 people taking the medicine. This frequency indicates it is a commonly observed pattern. Questions or concerns about the severity or persistence of side effects can be discussed with a healthcare provider.

Q: Does Femar cause changes in weight?

Official regulatory documents report that weight gain is listed as a common side effect of Femar. A common side effect is one that is reported in 1 out of 10 to 1 out of 100 people taking the medicine.

Q: What kind of monitoring (blood tests) is usually required while on Femar?

The prescribing information indicates that the healthcare provider may consider monitoring both Bone Mineral Density (BMD) and serum cholesterol. These checks are suggested to monitor for potential long-term effects on bone health and cardiovascular risk associated with the medicine's action.

Q: What is the difference between brand name Femar and the generic version?

Femar is the brand name for the active ingredient Letrozole. Generic versions of Letrozole are approved by regulatory agencies and are required to be bioequivalent. This means they contain the same active ingredient and achieve the same concentration in the bloodstream as the brand-name product.

Q: What is the half-life of Femar?

The terminal elimination half-life of the medicine is approximately 2 days. The half-life is a measure of the time it takes for half of the drug to be cleared from the body.

Q: Can Femar affect my mood or sleep?

Official adverse reaction reports include low mood or depression and insomnia (difficulty sleeping) as possible side effects.

Q: Is hair loss a possible side effect of Femar?

Hair loss or thinning (alopecia) is listed as a common side effect in the regulatory documentation. This adverse reaction is noted in the official regulatory documentation.

Q: Can Femar be taken with vitamins or herbal supplements?

The regulatory documents note a contraindication with estrogen-containing therapies. Therefore, products such as some herbal supplements that contain estrogen-like compounds may be discouraged as they could interfere with the medicine's core purpose of lowering estrogen levels.

Q: What should I know about combining Femar with alcohol?

Combining this medicine with alcohol may potentially increase certain central nervous system side effects. These can include dizziness, sleepiness, and somnolence. Official reports indicate that these effects may be amplified when combined with alcohol.

Q: Is there a maximum amount of time a person can be on Femar?

The approved duration of therapy is structured by the specific condition being treated, as established by regulatory studies. For example, use may be specified as four to eight months for pre-operative use, or continued for five years for adjuvant treatment.

Q: Is Femar a chemotherapy drug?

No, the medicine is classified as a hormonal therapy, specifically a Third-Generation Aromatase Inhibitor. It works by targeting hormone production in the body, which is a different mechanism than that of traditional chemotherapy drugs.

Q: Why do some people take Femar for a shorter time and others for a longer time?

The length of treatment is directly determined by the specific regulatory indication (the condition being treated). Treatment periods are set based on clinical trial evidence, such as four to eight months for pre-operative use, five years for adjuvant treatment, or continued until tumor progression in the advanced setting.

Q: Do I need to change my diet while taking Femar?

The official label states that the absorption of the medicine is not affected by food, meaning it can be taken with or without meals. There are no general dietary requirements specified in the regulatory documentation.

Q: Are there studies on the use of Femar in women of different ethnic backgrounds?

Regulatory overviews concerning the research acknowledge that subgroup findings are uncertain when trying to generalize data to patient populations that were not well represented in the major clinical trials. This highlights a known research gap in data sufficiency for certain groups.

Q: Is the research on Femar still ongoing?

Research in the area of hormonal and targeted therapies, including this medicine, is officially stated as ongoing in the regulatory documents. This typically involves comparative studies against the newest available treatments.

How should Femar be stored and disposed of?

Storage and Environmental Requirements

Femara (letrozole) tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The official label permits temporary temperature excursions between 15 C and 30 C (59 F and 86 F). The product must be protected from freezing, excess heat, and moisture and kept in its original container, tightly closed, to maintain stability.

Handling and Disposal

The medicine is required to be stored out of the sight and reach of children for safety. For disposal of unused or expired tablets, the official protocol recommends using a drug take-back program where available. If a take-back program is not accessible, the medication can be discarded by mixing it with an undesirable substance (such as dirt) and placing the mixture in a sealed container before putting it in the household trash. The original container's label must have all personal information scratched out.

Femar